Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers

Douglas M. Noonan, Alessandro Gringeri, Raffaella Meazza, Ombretta Rosso, Stefania Mazza, Myrvet Muça-Perja, Hélène Le Buanec, Roberto S. Accolla, Adriana Albini, Silvano Ferrini

Research output: Contribution to journalArticle

Abstract

We analyzed the epitopes and the molecular forms of Tat recognized by the antibodies raised by Tat-toxoid vaccination in both healthy and HIV-infected volunteers. Tat-toxoid - vaccinated healthy volunteer sera reacted predominantly with peptides covering amino acids 1 through 24 and 46 through 60, corresponding to the N-terminus and basic domains of Tat. In contrast, whereas all sera from vaccinated HIV-1 - positive patients reacted with the N-terminus and (with a single exception) with the basic domain, most of these sera also recognized peptides encompassing distinct domains of Tat, particularly the C-terminus (79-86). The sera of vaccinated individuals recognized both monomeric and oligomeric forms of Tat 1 through 86 or of Tat 1 through 101 and also blocked the ability of cell-released extracellular Tat to transactivate the HIV-1 LTR promoter. Synthetic Tat preincubated with sera from vaccinated individuals lost its functional activity as well. This is probably because of its inability to enter the cells as a result of immune complex formation with anti-Tat IgG. These data demonstrate that Tat-toxoid vaccination induces an efficient antibody response blocking the functional activity of Tat.

Original languageEnglish
Pages (from-to)47-55
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume33
Issue number1
Publication statusPublished - May 1 2003

Fingerprint

Immunodominant Epitopes
HIV-1
Volunteers
Toxoids
Serum
Vaccination
HIV Long Terminal Repeat
Peptides
Antigen-Antibody Complex
Antibody Formation
Epitopes
Healthy Volunteers
HIV
Amino Acids
Antibodies

Keywords

  • Epitope mapping
  • HIV
  • Humoral response
  • Kaposi sarcoma
  • Tat
  • Vaccine

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers. / Noonan, Douglas M.; Gringeri, Alessandro; Meazza, Raffaella; Rosso, Ombretta; Mazza, Stefania; Muça-Perja, Myrvet; Le Buanec, Hélène; Accolla, Roberto S.; Albini, Adriana; Ferrini, Silvano.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 33, No. 1, 01.05.2003, p. 47-55.

Research output: Contribution to journalArticle

Noonan, DM, Gringeri, A, Meazza, R, Rosso, O, Mazza, S, Muça-Perja, M, Le Buanec, H, Accolla, RS, Albini, A & Ferrini, S 2003, 'Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers', Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 1, pp. 47-55.
Noonan, Douglas M. ; Gringeri, Alessandro ; Meazza, Raffaella ; Rosso, Ombretta ; Mazza, Stefania ; Muça-Perja, Myrvet ; Le Buanec, Hélène ; Accolla, Roberto S. ; Albini, Adriana ; Ferrini, Silvano. / Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers. In: Journal of Acquired Immune Deficiency Syndromes. 2003 ; Vol. 33, No. 1. pp. 47-55.
@article{c48e8cffeb784205a78fc5ae4f023b98,
title = "Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers",
abstract = "We analyzed the epitopes and the molecular forms of Tat recognized by the antibodies raised by Tat-toxoid vaccination in both healthy and HIV-infected volunteers. Tat-toxoid - vaccinated healthy volunteer sera reacted predominantly with peptides covering amino acids 1 through 24 and 46 through 60, corresponding to the N-terminus and basic domains of Tat. In contrast, whereas all sera from vaccinated HIV-1 - positive patients reacted with the N-terminus and (with a single exception) with the basic domain, most of these sera also recognized peptides encompassing distinct domains of Tat, particularly the C-terminus (79-86). The sera of vaccinated individuals recognized both monomeric and oligomeric forms of Tat 1 through 86 or of Tat 1 through 101 and also blocked the ability of cell-released extracellular Tat to transactivate the HIV-1 LTR promoter. Synthetic Tat preincubated with sera from vaccinated individuals lost its functional activity as well. This is probably because of its inability to enter the cells as a result of immune complex formation with anti-Tat IgG. These data demonstrate that Tat-toxoid vaccination induces an efficient antibody response blocking the functional activity of Tat.",
keywords = "Epitope mapping, HIV, Humoral response, Kaposi sarcoma, Tat, Vaccine",
author = "Noonan, {Douglas M.} and Alessandro Gringeri and Raffaella Meazza and Ombretta Rosso and Stefania Mazza and Myrvet Mu{\cc}a-Perja and {Le Buanec}, H{\'e}l{\`e}ne and Accolla, {Roberto S.} and Adriana Albini and Silvano Ferrini",
year = "2003",
month = "5",
day = "1",
language = "English",
volume = "33",
pages = "47--55",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers

AU - Noonan, Douglas M.

AU - Gringeri, Alessandro

AU - Meazza, Raffaella

AU - Rosso, Ombretta

AU - Mazza, Stefania

AU - Muça-Perja, Myrvet

AU - Le Buanec, Hélène

AU - Accolla, Roberto S.

AU - Albini, Adriana

AU - Ferrini, Silvano

PY - 2003/5/1

Y1 - 2003/5/1

N2 - We analyzed the epitopes and the molecular forms of Tat recognized by the antibodies raised by Tat-toxoid vaccination in both healthy and HIV-infected volunteers. Tat-toxoid - vaccinated healthy volunteer sera reacted predominantly with peptides covering amino acids 1 through 24 and 46 through 60, corresponding to the N-terminus and basic domains of Tat. In contrast, whereas all sera from vaccinated HIV-1 - positive patients reacted with the N-terminus and (with a single exception) with the basic domain, most of these sera also recognized peptides encompassing distinct domains of Tat, particularly the C-terminus (79-86). The sera of vaccinated individuals recognized both monomeric and oligomeric forms of Tat 1 through 86 or of Tat 1 through 101 and also blocked the ability of cell-released extracellular Tat to transactivate the HIV-1 LTR promoter. Synthetic Tat preincubated with sera from vaccinated individuals lost its functional activity as well. This is probably because of its inability to enter the cells as a result of immune complex formation with anti-Tat IgG. These data demonstrate that Tat-toxoid vaccination induces an efficient antibody response blocking the functional activity of Tat.

AB - We analyzed the epitopes and the molecular forms of Tat recognized by the antibodies raised by Tat-toxoid vaccination in both healthy and HIV-infected volunteers. Tat-toxoid - vaccinated healthy volunteer sera reacted predominantly with peptides covering amino acids 1 through 24 and 46 through 60, corresponding to the N-terminus and basic domains of Tat. In contrast, whereas all sera from vaccinated HIV-1 - positive patients reacted with the N-terminus and (with a single exception) with the basic domain, most of these sera also recognized peptides encompassing distinct domains of Tat, particularly the C-terminus (79-86). The sera of vaccinated individuals recognized both monomeric and oligomeric forms of Tat 1 through 86 or of Tat 1 through 101 and also blocked the ability of cell-released extracellular Tat to transactivate the HIV-1 LTR promoter. Synthetic Tat preincubated with sera from vaccinated individuals lost its functional activity as well. This is probably because of its inability to enter the cells as a result of immune complex formation with anti-Tat IgG. These data demonstrate that Tat-toxoid vaccination induces an efficient antibody response blocking the functional activity of Tat.

KW - Epitope mapping

KW - HIV

KW - Humoral response

KW - Kaposi sarcoma

KW - Tat

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0038034441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038034441&partnerID=8YFLogxK

M3 - Article

C2 - 12792355

AN - SCOPUS:0038034441

VL - 33

SP - 47

EP - 55

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -